

HEMATOLOGY DISEASE SITE COMMITTEE

CHELSEA HOTEL, TORONTO, ON
ROOM: MOUNTBATTEN B
APRIL 30, 2023 8:00 AM – 12:00 PM

CO-CHAIRS : ANTHONY REIMAN, SARIT ASSOULINE
SENIOR INVESTIGATORS: ANNETTE HAY, LOIS SHEPHERD

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical trial and translational research, the disease burden associated with hematologic malignancies in Canada
- To identify clinical trial research opportunities in hematologic malignancies within the Canadian Cancer Trials Group
- To integrate current knowledge regarding therapeutics and tumour biology in hematologic malignancies in trial concept development and conduct
- To integrate and apply new clinical trial methodologies in hematologic malignancies in the Canadian Cancer Trials Group research agenda
- To provide a learning and mentoring environment supportive to new investigators

8:00 am	Welcome	Anthony Reiman, Sarit Assouline
8:15 am	Year's Accomplishments	Anthony Reiman
8:30 am	Primary Refractory vs. Relapsed DLBCL	David Scott
9:15 am	Spotlight on Hodgkin	
	Overall vision for HD	
	HDC.1	Kelly Davison / Michael Crump
	HD.12 -RADAR	Michael Crump
	HD.11	Kerry Savage
10:00 am	Break	
10:15 am	Ongoing/Soon to Open Studies	
	IND.244	Jean-Francois Larouche, Anca Prica
	CLC.3	Versha Banerji
	CLC.3E	Matt Cheung
	MYC.2	Chris Venner
	LY.17	John Kuruvilla
	LY.18	Diego Villa
	ALC.6	Lynn Savoie
	SC.26	Pierre Villeneuve
	myeloMATCH suite	Lynn Savoie, Sarit Assouline
11:30 am	Future Directions/Working Group Reports	All



11:35 am Closing Remarks

Anthony Reiman, Sarit Assouline

12:00 pm Meeting Adjourned



Canadian Cancer Society
Société canadienne du cancer

CCTG is a CCS national program.